<div id="readability-page-1">Atossa Therapeutics, Inc. ( ATOS ) stock is trading higher on Thursday. Here’s what investors need to know. <ul> <li>Atossa Therapeutics ( ATOS ) shares are climbing with conviction. What’s driving ATOS stock higher?</li> </ul> What To Know: The FDA granted one of the biopharmaceutical company’s potential treatments, (Z)-Endoxifen, a rare pediatric disease designation for the treatment of Duchenne Muscular Dystrophy. The status is typically reserved for drug candidates that treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age. The status gives (Z)-Endoxifen eligibility for a priority review voucher, which can be used to obtain priority review for a future application or may be sold or transferred to another sponsor. The drug candidate must first clear a qualifying marketing application. “This designation is an important regulatory milestone for Atossa, and we believe a strong validation of the science supporting the potential of (Z)-Endoxifen as a treatment for Duchenne Muscular Dystrophy,” said Steven Quay, CEO of the company. Atossa Therapeutics ( ATOS ) has not brought in revenue since 2016, according to Benzinga Pro. The company has reported a loss of 7 cents per share for the past two quarters. ATOS Price Action: Shares of Atossa were up 9.41%, trading at approximately 93 cents at the time of publication, according to Benzinga Pro. Read More: <ul> <li>Why Did Clearmind Medicine Shares Plunge 29% After Hours?</li> </ul> Image: Shutterstock</div>

ATOS

Atossa Therapeutics 的股票在 FDA 授予其潜在治疗药物 (Z)-Endoxifen 针对杜氏肌营养不良症的罕见儿童疾病认定后上涨了 9.41%。这一认定使其有资格获得优先审查凭证，增强了该药物未来申请的前景。首席执行官 Steven Quay 强调这是一个重要的监管里程碑。尽管自 2016 年以来未产生收入并报告亏损，但股票的上涨反映了投资者的乐观情绪

为什么 Atossa Therapeutics 的股票今天会上涨？